National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 1) (Cth)

PB 7 of 2022

National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 1)

I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make the following determination.

Dated               27 January 2022                     

NIKOLAI TSYGANOV

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Schedules................................................................................................................................. 1

Schedule 1—Amendments  2

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)                2

1  Name

This instrument is the National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 1).

This instrument may also be cited as PB 7 of 2022.

2  Commencement

(1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1.  The whole of this instrument	1 February 2022.

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

This instrument is made under subsection 85AB(1) of the National Health Act 1953.

4  Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)

1  Schedule 1, after item dealing with Dexamfetamine 

omit:

Dimethyl fumarate

2 Schedule 1, after item dealing with Fingolimod 

omit:

Fludrocortisone

3  Schedule 1, after item dealing with Galcanezumab

omit:

Glatiramer

4  Schedule 1, after item dealing with Magnesium

omit:

Mefenamic acid

5  Schedule 1, after item dealing with Mepolizumab

omit:

Mesalazine

6 Schedule 2, after item dealing with Diltiazem

insert:

Dimethyl fumarate 

7  Schedule 2, after item dealing with Fludarabine

insert:

Fludrocortisone 

8  Schedule 2, after item dealing with Gentamicin

insert:

Glatiramer  

9  Schedule 2, after item dealing with Medroxyprogesterone

insert:

Mefenamic acid

10  Schedule 2, after item dealing with Mercaptopurine

insert:

Mesalazine